Read Gene

Read Gene Debt

The Debt of Read Gene (RDG.WA) as of Nov 5, 2026 is 8.30 M PLN. In the previous year, Debt was 7.91 M PLN — a change of 4.95% (higher).

Debt

8.30 MPLN

YoY

4.95%

Last updated:

In 2025, Read Gene's total debt was 8.30 M PLN, a 4.95% change from the 7.91 M PLN total debt recorded in the previous year.

The Read Gene Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2016
262,870.00 PLN
Jan 1, 2017
420,780.00 PLN
Jan 1, 2020
4.26 M PLN
Jan 1, 2021
4.86 M PLN
Jan 1, 2022
7.06 M PLN
Jan 1, 2023
7.52 M PLN
Jan 1, 2024
7.91 M PLN
Jan 1, 2025
8.30 M PLN
The Read Gene Debt history
YEARDebtYoY
8.30 MPLN+4.95%
7.91 MPLN+5.20%
7.52 MPLN+6.52%
7.06 MPLN+45.13%
4.86 MPLN+14.03%
4.26 MPLN+913.37%
420,780.00PLN+60.07%
262,870.00PLN-70.42%
888,800.00PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Debt Details

Understanding Read Gene's Debt Structure

Read Gene's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Read Gene's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Read Gene’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Read Gene’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Read Gene stock

Debt of Read Gene is 8.30 M PLN in 2025.

Debt of Read Gene changed from 7.91 M PLN to 8.30 M PLN, representing a 4.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Read Gene since 2006 – with annual values, charts, and detailed analysis.

Debt's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Read Gene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Read Gene

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Read Gene